Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
29.24
+1.02 (3.61%)
At close: Aug 5, 2025, 4:00 PM
29.82
+0.58 (1.98%)
After-hours: Aug 5, 2025, 7:25 PM EDT
Lions Gate Entertainment Revenue
Crinetics Pharmaceuticals had revenue of $361.00K in the quarter ending March 31, 2025, a decrease of -43.59%. This brings the company's revenue in the last twelve months to $760.00K, down -61.50% year-over-year. In the year 2024, Crinetics Pharmaceuticals had annual revenue of $1.04M, down -74.11%.
Revenue (ttm)
$760.00K
Revenue Growth
-61.50%
P/S Ratio
3,604.22
Revenue / Employee
$1,739
Employees
437
Market Cap
2.74B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.04M | -2.97M | -74.11% |
Dec 31, 2023 | 4.01M | -724.00K | -15.28% |
Dec 31, 2022 | 4.74M | 3.66M | 339.42% |
Dec 31, 2021 | 1.08M | 1.01M | 1,418.31% |
Dec 31, 2020 | 71.00K | -1.12M | -94.05% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CRNX News
- 23 days ago - Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025 - GlobeNewsWire
- 25 days ago - Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewsWire
- 26 days ago - Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline - GlobeNewsWire
- 7 weeks ago - Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 - GlobeNewsWire
- 2 months ago - Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 - GlobeNewsWire